# H11-PREVENTIVA — Preventive Medicine, Screening & Healthspan

> **Layer 1** · Medicine & Health Sciences · `H11-PREVENTIVA`

## Purpose
The **H11-PREVENTIVA** agent serves as the core computational engine for primary, secondary, and quaternary preventive medicine within the H11 cognitive architecture. It models longitudinal disease etiology, calculates multi-system risk scores (cardiovascular-kidney-metabolic [CKM], cancer, osteoporotic, and neurodegenerative), optimizes evidence-based screening schedules (USPSTF, ACS, WHO), predicts vaccine-induced immunological persistence and antibody waning kinetics, estimates phenotypic biological age (PhenoAge/GrimAge proxies), and provides quaternary prevention guardrails against overdiagnosis and medical cascades.

By synthesizing multi-omic, clinical, lifestyle, and epidemiological parameters, H11-PREVENTIVA delivers dynamic, patient-tailored healthspan optimization protocols that prioritize high-yield interventions while minimizing iatrogenic harm.

---

## Technical Deep-Dive

### 1. Multi-System Risk Stratification & CKM Modeling
H11-PREVENTIVA implements composite clinical risk engines:
- **AHA/ACC Pooled Cohort Equations & PREVENT (2023) Algorithms:** Evaluates 10-year and 30-year risks of atherosclerotic cardiovascular disease (ASCVD) and heart failure, incorporating estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (uACR).
- **CKM (Cardiovascular-Kidney-Metabolic) Health Syndrome Staging:** Categorizes patients across Stages 0 (no risk factors), 1 (excess adiposity/dysglycemia), 2 (metabolic risk factors & moderate/high kidney risk), 3 (early subclinical CVD/high-risk CKD), and 4 (clinical CVD with metabolic/kidney disease).
- **Multi-Cancer Risk Modeling:** Incorporates modified Gail models (breast cancer), USPSTF pack-year criteria (lung low-dose CT), and polygenic risk score (PRS) priors for colorectal, prostate, and ovarian malignancies.

### 2. Biological Age & Physiological Reserve Kinetics
The agent computes phenotypic biological aging based on the validated **PhenoAge** mortality hazard matrix:
$$\text{PhenoAge} = 141.50 + \frac{\ln\left(-\ln\left(1 - \text{MortalityScore}\right)\right)}{0.090165}$$
$$\text{MortalityScore} = 1 - \exp\left(-\exp(xb) \cdot \frac{\exp(0.0076887 \cdot 120) - 1}{0.0076887}\right)$$
where $xb$ represents a linear combination of 9 clinical chemistry biomarkers (albumin, creatinine, glucose, log-transformed hs-CRP, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count) alongside chronological age.

### 3. Bayesian Screening Optimization & Lead-Time Bias Mitigation
Screening intervals for colonoscopy, mammography, Pap/HPV, low-dose chest CT, and bone mineral density (DEXA) are scheduled using continuous-time Markov decision processes (MDPs). The agent balances:
- Pre-test disease prevalence adjusted for family history and genomic load.
- Sensitivity/specificity curves across diagnostic modalities (e.g., FIT vs. Cologuard vs. Colonoscopy).
- Number Needed to Screen (NNS) vs. Number Needed to Harm (NNH), mitigating overdiagnosis cascades and unnecessary invasive biopsies.

### 4. Immunization Kinetics & Prophylaxis Tracking
The agent maintains dynamic vaccination ledgers adhering to CDC ACIP and WHO SAGE frameworks:
- Models antigen-specific antibody decay curves ($T_{1/2}$ decay kinetics).
- Evaluates travel-related chemoprophylaxis (malaria, yellow fever) and post-exposure prophylaxis (PEP/PrEP for HIV, rabies, tetanus toxoid).
- Identifies immunosuppression contraindications for live-attenuated vaccines (e.g., MMR, Varicella, Yellow Fever).

---

## Architecture

### Input Contract
| Field | Type | Description |
|---|---|---|
| `profile` | `PatientProfile` | Demographics, chronological age, sex, BMI, smoking history, family pedigree |
| `biomarkers` | `PhenotypicBiomarkers` | Fasting glucose, HbA1c, hs-CRP, lipid subfractions, eGFR, uACR, CBC, liver enzymes |
| `screening_history`| `List[ScreeningRecord]` | Previous screening modalities, dates, findings, and pathology reports |
| `vaccination_ledger`| `List[VaccineRecord]` | Antigen exposures, dates, brand, and adverse event history |
| `lifestyle_metrics` | `LifestyleData` | Cardiorespiratory fitness ($\text{VO}_2\text{ max}$), sleep architecture, dietary scores, alcohol units |

### Output Contract
| Field | Type | Description |
|---|---|---|
| `risk_stratification` | `RiskStratificationReport` | ASCVD 10-year score, CKM stage, cancer screening eligibility, metabolic syndrome status |
| `biological_age` | `BiologicalAgeResult` | Phenotypic biological age, age delta ($\Delta\text{Age} = \text{PhenoAge} - \text{Chronological}$), key age-accelerating drivers |
| `screening_schedule` | `List[ScreeningRecommendation]` | USPSTF-aligned screening directives, recommended intervals, NNS/NNH disclosures |
| `immunization_audit`| `ImmunizationScheduleAudit` | Due/overdue vaccines, antibody titer recommendations, travel/occupational requirements |
| `quaternary_alerts` | `List[QuaternaryAlert]` | Warnings on low-value testing, excessive screening frequency, or cascade biopsy risks |
| `prevention_plan` | `ComprehensivePreventivePlan`| Unified actionable roadmap for primary, secondary, and quaternary optimization |

### State Schema
Maintains `PreventiveState` per patient tracking longitudinal risk vectors, screening compliance graphs, immunization antibody persistence models, and biological age trajectories over multi-year horizons.

---

## Dependencies

### Upstream (Depends On)
- `H11-EPIDEMIOLOGIA`: For population incidence baselines, epidemic alerts, and regional prevalence weights.
- `H11-GENETICA-MED`: For polygenic risk scores (PRS) and monogenic cancer/cardiovascular predisposition variants (e.g., *BRCA1/2*, *LDLR*, *Lynch syndrome*).
- `H11-HEALTHINFORMATICA`: For structured EHR ingest, LOINC/SNOMED mapping, and encounter timelines.
- `H11-NUTRITIO`: For dietary micro/macronutrient patterns and metabolic energy expenditure data.

### Downstream (Feeds Into)
- `H11-CARDIOLOGIA`: Triggers early preventive cardiology consults when ASCVD risk > 7.5% or CAC score > 0.
- `H11-ENDOCRINOLOGIA`: Directs prediabetes and metabolic syndrome cohorts for metabolic intervention before overt type 2 diabetes onset.
- `H11-PNEUMOLOGIA`: Routes high-risk smokers to structured low-dose CT lung cancer screening and smoking cessation pipelines.
- `H11-PALLIATIVA`: Supplies multi-morbidity burden and frailty risk indices to inform goals-of-care and deprescribing transitions.

---

## Failure Modes & Safeguards
1. **Overdiagnosis Cascades:** Indiscriminate whole-body screening can trigger incidentaloma workups. *Mitigation: Strict adherence to USPSTF Grade A/B recommendations with explicit quaternary prevention gates.*
2. **Extrapolation Beyond Validated Age Ranges:** Applying pooled cohort equations outside ages 20–79 produces inaccurate absolute risk estimates. *Mitigation: Age-range boundary assertion checks and transition to lifetime risk or frailty-adjusted scoring.*
3. **Immunocompromise Live Vaccine Violation:** Inadvertent administration of live vaccines in severely immunosuppressed patients. *Mitigation: Hard assertion checks cross-referencing CD4 count, immunosuppressive biologics, and chemotherapy history.*
4. **False Reassurance from Low Short-Term Risk:** Young patients with severe single risk factors (e.g., LDL-C $\ge 190\text{ mg/dL}$) showing low 10-year risk. *Mitigation: Lifetime risk calculation and automated guideline-directed statin prompts.*

---

## Performance Characteristics
- Multi-condition risk calculation & CKM staging: **< 10ms** per patient.
- Phenotypic biological age determination: **< 2ms**.
- Full lifetime preventive schedule synthesis: **< 40ms**.
- Memory footprint: **< 25MB** for active working state across 10,000 longitudinal profiles.

---

## Research References
1. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan: The PhenoAge clock. *Aging (Albany NY)*. 2018;10(4):573-591.
2. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2023;148(20):1606-1635.
3. US Preventive Services Task Force (USPSTF). Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (AHRQ); 2023.
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol*. 2019;73(24):e285-e350.
5. Jamieson DJ, et al. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule. *MMWR Morb Mortal Wkly Rep*. 2024.

---

## Implementation Notes
- Pure Python 3.10+ typing with standard mathematical and statistical libraries.
- Implements numerical safeguards against log-of-negative or zero values during PhenoAge calculation.
- Designed for asynchronous integration within the H11 multi-agent diagnostic-preventive loop.
